Black Rock Inc. Hcw Biologics Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Hcw Biologics Inc. stock. As of the latest transaction made, Black Rock Inc. holds 42,662 shares of HCWB stock, worth $16,638. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,662

Previous 46,034 7.33%

Holding current value

$16,638

Previous $80,000 66.25%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.64 - $1.68 $2,158 - $5,664	-3,372 Reduced 7.33%	42,662 $27,000
Q1 2024 May 10, 2024	SELL	$1.1 - $1.77 $1,236 - $1,989	-1,124 Reduced 2.38%	46,034 $80,000
Q4 2023 Feb 13, 2024	SELL	$0.92 - $2.14 $517 - $1,202	-562 Reduced 1.18%	47,158 $58,000
Q3 2023 Nov 13, 2023	SELL	$1.75 - $2.31 $3,442 - $4,543	-1,967 Reduced 3.96%	47,720 $90,000
Q2 2023 Aug 11, 2023	BUY	$1.35 - $2.3 $7,588 - $12,928	5,621 Added 12.76%	49,687 $107,000
Q1 2023 May 12, 2023	BUY	$1.12 - $2.19 $1,592 - $3,114	1,422 Added 3.33%	44,066 $61,000
Q4 2022 Feb 13, 2023	BUY	$1.84 - $2.36 $1,744 - $2,237	948 Added 2.27%	42,644 $81,000
Q3 2022 Nov 14, 2022	SELL	$2.13 - $2.74 $2,524 - $3,246	-1,185 Reduced 2.76%	41,696 $96,000
Q2 2022 Aug 12, 2022	BUY	$1.96 - $3.17 $6,464 - $10,454	3,298 Added 8.33%	42,881 $94,000
Q1 2022 May 12, 2022	BUY	$1.9 - $2.73 $43,451 - $62,432	22,869 Added 136.83%	39,583 $108,000
Q4 2021 Feb 10, 2022	BUY	$2.32 - $4.73 $1,009 - $2,057	435 Added 2.67%	16,714 $39,000
Q3 2021 Nov 09, 2021	BUY	$3.14 - $6.3 $51,116 - $102,557	16,279 New	16,279 $52,000

Others Institutions Holding HCWB

# of Institutions

Shares Held

3.13M

Call Options Held

Put Options Held

View Full List

About HCW Biologics Inc.

Ticker HCWB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,833,100
Market Cap $14M
Description
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal...

More about HCWB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account